TIVA Versus Balanced Anesthesia on Muscle Mass in CRC Surgery
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: total intravenous anaesthesia, sevoflurane anaesthesia.
- Who it may be relevant to
- Registry conditions: Colorectal Cancer (CRC), Sarcopenia. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Romania
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Total Intravenous Anesthesia Versus Balanced Anesthesia on Loss of Muscle Mass After Colorectal Cancer Surgery
Overview
This study is aimed at clarifying changes in body composition during the perioperative period and identifying risk factors for skeletal muscle mass loss in patients with colorectal cancer. The investigators will asess the impact of the type of anaesthesia (total intravenous anaesthesia/sevoflurane anaesthesia) for colorectal surgery on the muscle function and mass, which will be evaluated using ultrasound, dynamometry and bioimpedance.
Interventions
- Procedure total intravenous anaesthesia
evaluate the impact of the type of anaesthesia (total intravenous anaesthesia (TIVA)/sevoflurane anaesthesia) for colorectal surgery on the muscle function and mass - Procedure sevoflurane anaesthesia
evaluate the impact of the type of anaesthesia (total intravenous anaesthesia (TIVA)/sevoflurane anaesthesia) for colorectal surgery on the muscle function and mass
Primary outcome measures
- Ultrasonographic assessment of muscle mass [Time frame: From enrollment to 5 days after surgery]
- Muscle function assessment [Time frame: From enrollment to 5 days after surgery]
- Bioimpedance assessment of lean and fat tissue mass [Time frame: From enrollment to 5 days after surgery]
Secondary outcome measures (2)
- Hospital length of stay [Time frame: From enrollment to the patient discharge, up to 52 weeks]
- Mortality [Time frame: 28 and 90-day mortality after surgery]
Eligibility criteria
Inclusion criteria
- adult patients diagnosed with colorectal cancer and scheduled for open colorectal surgery at the Regional Institute of Oncology, Iaşi, Romania
Exclusion criteria
- lack the capacity to consent
- extremity amputation
- paraplegia
- diseases affecting the muscles (such as stroke, lower-limb immobilization from a plaster, neurodegenerative diseases, peripheral neuropathy or muscle dystrophy)
- terminal cancer
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
Romania · 1 center
- Regional Institute of Oncology, Iaşi, Romania — Iași
Identifiers
NCT: NCT07237438 · 358/11.08.2025